View Older Stories View More Recent Stories
-
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
-
Lexaria extends pharmaceutical partnership agreement through April 2026
-
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
-
Lexaria Bioscience hires advisory firm, receives 4 new patents
-
Lexaria Bioscience Corp. Provides Strategic Update
-
Lexaria Bioscience closes $4 million registered direct offering
-
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Lexaria reports enhanced brain delivery of semaglutide using DehydraTECH
-
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
-
Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
-
Lexaria completes patient dosing in Phase 1b GLP-1 study
-
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
-
GLP-1 "Arms Race" Broadens to Include Dozens of Companies
-
Lexaria reports reduced side effects in GLP-1 drug trial
-
Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
-
Lexaria claims technology could reduce GLP-1 drug side effects
-
Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
-
Lexaria Bioscience (LEXX) Reaches Patent Milestone - 50 Patents Now Granted Worldwide
-
Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
-
Lexaria's (LEXX) DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
-
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
-
Lexaria Attending BIO International Convention
-
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock
-
Lexaria Bioscience (LEXX) Prices 2M Share Offering at $1/sh
-
Lexaria Announces $2 Million Registered Direct Offering of Common Stock
-
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
-
Lexaria Bioscience (LEXX) announces human dosing in GLP-1 study
-
Lexaria's Human GLP-1 Study #5 Begins Dosing
-
Lexaria Bioscience's (LEXX) DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound
-
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
-
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
-
Lexaria Bioscience (LEXX) Reports Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
-
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
-
Lexaria Bioscience (LEXX) Strategic Business Pursuit of DehydraTECH-Liraglutide
-
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
-
Lexaria Bioscience (LEXX) Granted Two New DehydraTECH Patents for Treatment of Epilepsy
-
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
-
Lexaria Bioscience (LEXX) Biodistribution Study For DehydraTECH GLP-1 is Underway
-
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
-
Lexaria Bioscience (LEXX) Releases Annual Letter from the CEO
-
Lexaria Releases Annual Letter from the CEO
-
Lexaria Bioscience's (LEXX) Human GLP-1 Study #5 Receives Independent Review Board Approval
-
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
-
Lexaria Bioscience's (LEXX) Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound
-
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
-
Lexaria's Registered GLP-1 Study #4 Begins Dosing
-
Lexaria Bioscience (LEXX) Forms New Scientific Advisory Board
-
Lexaria Forms New Scientific Advisory Board
-
Lexaria Bioscience (LEXX) Appoints Michael Gibson as Chief Medical Advisor
-
Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
